CL2020002350A1 - Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3 - Google Patents

Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3

Info

Publication number
CL2020002350A1
CL2020002350A1 CL2020002350A CL2020002350A CL2020002350A1 CL 2020002350 A1 CL2020002350 A1 CL 2020002350A1 CL 2020002350 A CL2020002350 A CL 2020002350A CL 2020002350 A CL2020002350 A CL 2020002350A CL 2020002350 A1 CL2020002350 A1 CL 2020002350A1
Authority
CL
Chile
Prior art keywords
dual
pharmaceutical formulation
receptor antagonists
novel pharmaceutical
hexahydropyrazino
Prior art date
Application number
CL2020002350A
Other languages
English (en)
Inventor
Mike Trower
Mary Kerr
David Elder
Monica Lazaro
Derek Bush
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65817992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of CL2020002350A1 publication Critical patent/CL2020002350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a nuevas formulaciones farmacéuticas que contienen 2-[3,5-Bis(trifluorometil)fenil]-N-{4-(4-fluoro-2-metilfenil)-6-[(7S,9aS)-7-(hidroximetil)hexahidropirazino[2,1-c][1,4]oxazin-8(1H)-il]-3-piridinil}-N,2-dimetilpropanamida, métodos de preparación de los mismos y su uso en terapia médica.
CL2020002350A 2018-03-14 2020-09-11 Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3 CL2020002350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862642622P 2018-03-14 2018-03-14

Publications (1)

Publication Number Publication Date
CL2020002350A1 true CL2020002350A1 (es) 2021-04-16

Family

ID=65817992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002350A CL2020002350A1 (es) 2018-03-14 2020-09-11 Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3

Country Status (34)

Country Link
US (6) US10774091B2 (es)
EP (1) EP3765024B1 (es)
JP (1) JP7433252B2 (es)
KR (1) KR102833016B1 (es)
CN (2) CN112292132A (es)
AU (1) AU2019233606B2 (es)
CA (1) CA3092238A1 (es)
CL (1) CL2020002350A1 (es)
CO (1) CO2020011262A2 (es)
CR (1) CR20200385A (es)
DK (1) DK3765024T3 (es)
EA (1) EA202092131A1 (es)
EC (1) ECSP20057488A (es)
ES (1) ES2974300T3 (es)
FI (1) FI3765024T3 (es)
GE (2) GEAP202215464A (es)
HR (1) HRP20240120T1 (es)
HU (1) HUE065300T2 (es)
IL (1) IL276959B2 (es)
JO (1) JOP20200227B1 (es)
LT (1) LT3765024T (es)
MA (1) MA51999B1 (es)
MX (2) MX392190B (es)
MY (1) MY201590A (es)
PE (1) PE20210395A1 (es)
PH (1) PH12020551457A1 (es)
PL (1) PL3765024T3 (es)
PT (1) PT3765024T (es)
RS (1) RS65257B1 (es)
SA (1) SA520420126B1 (es)
SG (1) SG11202008226YA (es)
SI (1) SI3765024T1 (es)
UA (1) UA128159C2 (es)
WO (1) WO2019175253A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3512839A4 (en) 2016-09-18 2020-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. AGAINST INTERACTION OF YAP1 WITH YCT1 INHIBITORS
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
WO2019178401A1 (en) 2018-03-14 2019-09-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
EP4058433A1 (en) 2019-11-15 2022-09-21 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
CA3168199A1 (en) * 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
KR102484687B1 (ko) * 2022-03-04 2023-01-05 (주)씨앤엘디 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097618A (en) 1960-12-01 1963-07-16 Raymond Bag Corp Manufacture of multi-wall bag having heat-sealed liner
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
WO1996003138A1 (en) 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
DE60018707T2 (de) 1999-01-25 2006-02-09 Smithkline Beecham Corp. Anti-androgene und verfahren zur behandlung von krankheiten
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
WO2001095904A1 (en) 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
OA12619A (en) 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
JP4677235B2 (ja) 2002-12-23 2011-04-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換４−（４−ピペリジン−４−イル−ピペラジン−１−イル）−アゼパン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
JP2007537233A (ja) 2004-05-12 2007-12-20 ファイザー・プロダクツ・インク Ｎｋ１及びｎｋ３アンタゴニストとしてのピペリジン誘導体
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (en) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
JP2010502703A (ja) 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
DE602008001983D1 (de) 2007-04-20 2010-09-09 Hoffmann La Roche Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
ES2440938T3 (es) 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
SG11201402689XA (en) 2011-12-02 2014-06-27 Glaxosmithkline Ip No 2 Ltd Peptide deformylase inhibitors
KR101739820B1 (ko) 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
US20130302414A1 (en) 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US20150272927A1 (en) 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
JP6316932B2 (ja) 2013-03-29 2018-04-25 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
AU2016264034B2 (en) 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP4058433A1 (en) 2019-11-15 2022-09-21 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814

Also Published As

Publication number Publication date
IL276959B1 (en) 2024-03-01
EA202092131A1 (ru) 2020-11-27
AU2019233606B2 (en) 2024-10-03
SG11202008226YA (en) 2020-09-29
CR20200385A (es) 2021-05-21
MX2020009438A (es) 2022-05-11
JOP20200227B1 (ar) 2024-04-18
SA520420126B1 (ar) 2024-02-01
FI3765024T3 (fi) 2024-02-14
HRP20240120T1 (hr) 2024-04-12
PT3765024T (pt) 2024-02-19
KR102833016B1 (ko) 2025-07-14
JOP20200227A1 (ar) 2020-09-13
US20190284205A1 (en) 2019-09-19
US20230382922A1 (en) 2023-11-30
DK3765024T3 (da) 2024-02-12
CN112292132A (zh) 2021-01-29
MX392190B (es) 2025-03-21
LT3765024T (lt) 2024-02-26
US11767328B2 (en) 2023-09-26
US20200361956A1 (en) 2020-11-19
HUE065300T2 (hu) 2024-05-28
JP7433252B2 (ja) 2024-02-19
US10774091B2 (en) 2020-09-15
MA51999B1 (fr) 2024-02-29
MY201590A (en) 2024-03-04
UA128159C2 (uk) 2024-04-24
US12264164B2 (en) 2025-04-01
RS65257B1 (sr) 2024-03-29
AU2019233606A1 (en) 2020-09-17
MA51999A (fr) 2021-01-20
JP2021517590A (ja) 2021-07-26
US11591346B2 (en) 2023-02-28
ES2974300T3 (es) 2024-06-26
EP3765024B1 (en) 2023-11-22
IL276959A (en) 2020-10-29
US20230174552A1 (en) 2023-06-08
NZ767340A (en) 2025-11-28
KR20200139138A (ko) 2020-12-11
SI3765024T1 (sl) 2024-05-31
CN119950513A (zh) 2025-05-09
PL3765024T3 (pl) 2024-08-05
MX2022005706A (es) 2022-06-08
CA3092238A1 (en) 2019-09-19
US11787820B2 (en) 2023-10-17
GEP20237503B (en) 2023-04-25
PH12020551457A1 (en) 2021-11-22
EP3765024A1 (en) 2021-01-20
IL276959B2 (en) 2024-07-01
GEAP202215464A (en) 2022-11-25
CO2020011262A2 (es) 2020-12-10
ECSP20057488A (es) 2020-12-31
WO2019175253A1 (en) 2019-09-19
US20200361957A1 (en) 2020-11-19
US20250154167A1 (en) 2025-05-15
BR112020017388A2 (pt) 2020-12-15
PE20210395A1 (es) 2021-03-02

Similar Documents

Publication Publication Date Title
CO2020011262A2 (es) Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CL2019000714A1 (es) Derivados de pirazolo [1,5-a]piridina y su uso como pesticidas.
CL2018002806A1 (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
EP4249076A3 (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
DOP2019000104A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
MX372934B (es) Compuestos de imidazopiridina y sus usos.
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
CR20130210A (es) DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
PL3250208T3 (pl) 7-benzylo-4-(4-(trifluorometylo)benzylo)-1,2,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn-5(4h)-on oraz jego sole i ich zastosowanie w terapii
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2019001318A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EP3452455A4 (en) SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
BR112015023187A2 (pt) inibidores de pirrolo[2,3 - b] piridina cdk9 kinase
PE20200887A1 (es) Forma a-i de monoacetato de (s)-7-(4-(1-(metilsulfonil)piperidin-4-il)fenil)-n-(morfolin-2-ilmetil)pirido[3,4-b]pirazin-5-amina
TH2001005063A (th) สารผสมตามสูตรทางเภสัชกรรมใหม่ซึ่งประกอบรวมด้วย Dual NK-1/NK-3 รีเซพเตอร์ แอนทาโกนิสท์
PE20160007A1 (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
MX2023005909A (es) Formas cristalinas de 4-amino-n-[4-(metoximetil)fenil]-7-(1-metilc iclopropil)-6-(3-morfolinoprop-1-in-1-il)-7h-pirrolo[2,3-d]pirimi din-5-carboxamida, metodos de preparacion, y usos de las mismas.
AR108090A1 (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MX378367B (es) Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil-n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexanocarboxamida.
AR104315A1 (es) Compuestos de butanamida, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende, su uso para prepararla, y combinación y mezcla que lo comprenden